High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics

• Published in: Genome research Vol. 28; no. 9; pp. 1345 - 1352
• Main Authors: Pellegrino, Maurizio, Sciambi, Adam, Treusch, Sebastian, Durruthy-Durruthy, Robert, Gokhale, Kaustubh, Jacob, Jose, Chen, Tina X, Geis, Jennifer A, Oldham, William, Matthews, Jairo, Kantarjian, Hagop, Futreal, P Andrew, Patel, Keyur, Jones, Keith W, Takahashi, Koichi, Eastburn, Dennis J
• Format: Journal Article
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 01.09.2018
• Subjects: Acute myeloid leukemia; Aged; Cells, Cultured; Clonal Evolution; Deoxyribonucleic acid; DNA; DNA sequencing; Humans; Leukemia; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Male; Method; Microfluidics; Microfluidics - methods; Mutation; Myeloid leukemia; Next-generation sequencing; Remission; Sequence Analysis, DNA - methods; Single-Cell Analysis - methods; Tumors
• ISSN: 1088-9051; 1549-5469
• DOI: 10.1101/gr.232272.117

To enable the characterization of genetic heterogeneity in tumor cell populations, we developed a novel microfluidic approach that barcodes amplified genomic DNA from thousands of individual cancer cells confined to droplets. The barcodes are then used to reassemble the genetic profiles of cells from next-generation sequencing data. By using this approach, we sequenced longitudinally collected acute myeloid leukemia (AML) tumor populations from two patients and genotyped up to 62 disease relevant loci across more than 16,000 individual cells. Targeted single-cell sequencing was able to sensitively identify cells harboring pathogenic mutations during complete remission and uncovered complex clonal evolution within AML tumors that was not observable with bulk sequencing. We anticipate that this approach will make feasible the routine analysis of AML heterogeneity, leading to improved stratification and therapy selection for the disease.